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A dimeric ternary complex of FGFR1, heparin and FGF-1 leads to
an ‘electrostatic sandwich’ model for heparin binding
Mikko T Huhtala1†, Olli T Pentikäinen1† and Mark S Johnson2*
Background: Fibroblastic growth factors (FGFs) are a family of cytokines
involved in regulation of cell growth, differentiation and chemotaxis in a variety
of tissue types. High-affinity FGF receptors (FGFRs) are transmembrane
proteins that consist of three extracellular immunoglobulin-like domains, a
transmembrane helix and an intracellular protein tyrosine kinase signalling
domain. FGFRs are activated through ligand-dependent dimerization that allows
trans-autophosphorylation of the tyrosine kinase domains. Heparin or heparin-
like molecules, such as heparan sulphate proteoglycans, bind to both FGFs and
FGFRs and are required for FGF signal transduction. At present no structure of
the ternary complex for FGFR, FGF and heparin exists.
Results: We have used the type-1 interleukin-1 receptor–interleukin-1β
complex crystal structure, in which both the ligand and the receptor are
homologous to those of the FGF–FGFR pair, to identify potential interactions in
the FGFR–heparin–FGF ternary complex. A key feature of the modelled
complex is the ‘electrostatic sandwich’ that is formed between the positively
charged surfaces of FGF and the receptor, with the negatively charged heparin
captured in between. The ternary complex places limits on the range of likely
modes of receptor dimerization: one of five different dimeric receptor complexes
built from the ternary complex correlates best with the experimental data.
Conclusions: The ternary complex of FGFR, FGF and heparin, derived on the
basis of the homologous interleukin-1 receptor complex, is in agreement with
much of the published experimental data, as is the dimeric receptor complex
(FGFR–heparin–FGF)2. This work suggests that the FGF interactions seen in
crystal structures, which have previously been used to predict the mode of FGF
dimerization, might not be relevant to the biologically active dimeric
FGFR–heparin–FGF complex.
Introduction
High-affinity fibroblast growth factor (FGF) receptors
(FGFRs) are transmembrane proteins that — although no
three-dimensional structures exist for either the receptor
or a complex with growth factor — are generally accepted
to consist of three extracellular immunoglobulin-like
domains, a transmembrane helix and an intracellular
protein tyrosine kinase signalling domain. FGFRs are acti-
vated through ligand-dependent dimerization, which
allows trans-autophosphorylation of the tyrosine kinase
domains. Heparin or heparin-like molecules, such as
heparan sulphate proteoglycans, bind to both FGFs and
FGFRs and are required for FGF signal transduction
[1,2]. Cell-surface heparan sulphate proteoglycans have
been postulated to act as low-affinity FGF receptors that
capture the ligand and present it to the high-affinity signal
transducing receptors [3].
Four human FGFR genes have been described, three
of which encode multiple receptor forms as a result of 
alternative mRNA splicing. The FGFR4 gene [4] is about
60% identical with FGFR1–FGFR3, does not exhibit
alternative mRNA splicing and is expressed as a single
receptor form [5]. The ectodomain of FGFR4 shares
approximately 20% amino acid sequence identity
(Figure 1) with type-1 interleukin-1 receptor (IL1R) over
the three immunoglobulin-like domains (Ig1, Ig2 and
Ig3). IL1R forms a dimer upon activation with a homolo-
gous accessory protein (IL1RAcP, 25% sequence identity
with IL1R) that is indispensable for signal transduction
but does not bind IL-1 [6,7].
IL-1α, IL-1β and the IL-1 receptor antagonist (IL-1RA)
comprise a family of IL1R ligands, the members of which
have structures that share an antiparallel β-barrel fold and
are homologous to the FGF family. Crystal structures of
IL1R complexed with IL-1β (Figure 2a) and IL-1RA have
recently been solved [8,9]. The crystal structure [10] of
human FGF-1 (128 amino acids) can be superimposed on
IL-1β (153 amino acids) in the IL1R–IL-1β complex with a
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root mean squared (rms) deviation of 1.38 Å over 83 aligned
Cα atom pairs (within 3.0 Å of each other after alignment;
Figure 2b). The barrel fold β strands are conserved in
FGF-1 and IL-1β, whereas the loop regions are generally
longer in IL-1β. FGF-2, which is 57% identical to FGF-1,
also binds to FGFR4 but with lower affinity [11]. 
One recently reported model of the monomeric
FGFR–heparin–FGF ternary complex but without the first
immunoglobulin domain [12] is based on the IL1R–IL-1β
crystal structure, whereas the rest of the many different
published models for the monomeric ternary complex or
the dimeric receptor complex do not take into account
details from the related interleukin complex structure. We
will show that the incorporation of details from the crystal
structure of the IL1R–IL-1β complex leads to both a
ternary complex and dimeric receptor complex that are in
agreement with the majority of published experimental
results. Furthermore, a positively charged channel for
binding heparin arises as a consequence of mapping the
model of FGFR4 and the structure of FGF-1 onto the
interleukin complex without the need for any other manip-
ulations of the model. In contrast, there is little or no agree-
ment among the earlier models that were not based on the
IL1R–IL-1β structure, and there is often poor agreement
with the published experimental result.
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Figure 1
Sequence alignment of the FGFR4
ectodomain with IL1R and telokin. Note that
the telokin structure consists of a single Ig
domain and therefore the sequence is used
three times in the alignment, once for each
receptor domain Ig1, Ig2 and Ig3. Conserved
residues (in at least two of the three
sequences) are in bold type. Residues in
FGFR4 are marked as follows: +, positively
charged arginine and lysine residues
contributing to the heparin-binding channel; *,
hydrophobic residues at the high-affinity FGF
binding site; ^, residues in contact with the
FGF-1 low-affinity receptor-binding loop in the
dimer of Figure 4a. Portions of the alignment
that include structurally conserved regions
common to telokin and IL1R are enclosed in
boxes, and the disulphide-bond-forming
cysteines, as well as one completely
conserved tryptophan in each domain, are
shown on a black background. The acidic box
within the 26-residue insertion in the FGFR4
sequence that was not modelled, is shown in
uppercase italics. Five putative N-linked
glycosylation sites are shown in lowercase
italics. The numbering is according to the
FGFR4 sequence. The alignment was
formatted using ALSCRIPT [38].
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Structure
Results and discussion
We have constructed an FGFR4 ectodomain homology
model (Figure 2c) using as a template the crystal structure
of the IL1R–IL-1β complex [8], the only available crystal
structure of a receptor–ligand pair homologous to the
FGFR–FGF complex. As in many other receptors and
adhesion proteins, the fold of the FGFR and IL1R extra-
cellular domains has been predicted to belong to the
group within the immunoglobulin superfamily known as
the ‘I set’ [13,14]. A crystal structure of an I-set domain,
telokin (an intracellular protein) [15], was superposed on
each of the immunoglobulin (Ig) domains of the IL1R
structure in order to help position the key motifs in the
sequence alignment of FGFR4 with IL1R (Figure 1).
This alignment resulted in a model for FGFR4 that
reflects the conserved features found in aligned I-set
sequences [13] that are also matched in the superposed
structures of IL1R and telokin. Each of the three Ig
domains has a pair of conserved cysteine residues (Cys57
and Cys101 in Ig1 of FGFR4) forming a disulphide bond,
as is seen in the structure of IL1R, and a conserved trypto-
phan residue (Trp66 in Ig1 of FGFR4). These trypto-
phans are a part of the ‘WXK’ motif (in which X is a large
hydrophobic residue), which is conserved in all three
sequences in Figure 1. Furthermore, the second cysteine
residue participating in the disulphide bond in each
immunoglobulin domain in FGFR4 (Cys101 in Ig1 of
FGFR4) is preceded by partially conserved aspartate and
tyrosine residues (Asp95 and Tyr99 in Ig1 of FGFR4), and
a conserved glycine (Gly50 in Ig1 of FGFR4) is positioned
between the first and the second β strand of each domain
[13]. The extent of sequence identity of FGFR4 to IL1R
and telokin over the structurally conserved regions in the
two crystal structures (boxed in Figure 1) is a significant
24% and 26% (20% and 22% over the entire ectodomain),
respectively. Taken together, the similarity of FGFR4 to
both IL1R and telokin is compelling and the alignment
over the structurally conserved regions is given strong
support because key residues in each of the three
immunoglobulin domains are conserved in the homolo-
gous structures and anchor the alignment of the domains.
A 28-residue section (containing a 26-residue insertion in
FGFR4 relative to IL1R), between domains Ig1 and Ig2,
was not modelled. This sequence contains the so-called
acidic box (Figure 1), a stretch of acidic residues character-
istic of FGFRs which has been shown to bind divalent
cations such as calcium and copper [16]. The binding of
divalent cations to the acidic box increases the affinity of
FGFRs for both FGF ligands and heparin, with the
increased affinity thought to be the result of a conforma-
tional change in the receptor [16]. Because we have no
structural information concerning the 26 residues within
this insertion, its role in the structure and effect on the rel-
ative placement of the other domains remains unclear.
Nevertheless, as we shall show below, the orientation of
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Figure 2
Similarities between IL1R–IL-β and FGFR1–FGF-1 lead to an
electrostatic channel suitable for heparin binding. (a) Cα atom trace of
the IL1R–IL-1β complex. The three Ig domains of the receptor are
coloured green (Ig1), khaki (Ig2) and yellow (Ig3) in each panel.
(b) FGF-1 (blue) superposed on the structure of IL-1β (black) in the
IL1R–IL-1β complex structure. The loops in FGF-1 facing Ig1 and Ig2
are shorter than those in IL-1β, in part providing space for heparin to be
sandwiched in between the growth factor and its receptor. (c) The
model of the ternary complex between FGFR4, FGF-1 and heparin
(black ball-and-stick). (d) The electrostatic sandwich: positively charged
sidechains on the surface of the FGFR4 model and FGF-1 are coloured
black. (Top) View of the predicted heparin-binding channel (X) between
FGFR4 and FGF-1 in the ternary model; (bottom) orthogonal view:
heparin binds horizontally in the channel and across the FGFR–FGF-1
face in the direction of the X. The location of the N terminus of the
receptor is indicated. This figure was prepared using MOLSCRIPT [35].
Ig1 relative to FGF and based on the IL1R–IL-1β crystal
structure leads to the formation of a positively charged
channel that is ideal for heparin binding.
The general orientation of FGF-1 and heparin, in relation
to the receptor (Figure 2c), was pinpointed by superim-
posing onto the IL1R–IL-1β complex structure first a part
of the crystal structure [10] comprising one FGF-1 mol-
ecule plus bound heparin (onto IL-1β) and second the
FGFR4 model (onto IL1R). The crystal structures of
FGF-2–heparin and FGF-1–heparin–FGF-1 complexes
[10,17] show ordered saccharide units, clearly identifying
the conserved high-affinity heparin-binding site of the
two FGFs. For our purposes, we modelled a larger heparin
fragment that was then manually docked to the
FGFR4–FGF-1 model in order to build the ternary
complex (Figure 3).
The ternary FGFR–heparin–FGF complex
When the FGFR4 model and the structure of FGF-1
were superposed on the IL1R–IL-1β complex, an ‘elec-
trostatic sandwich’ is formed between FGFR4, heparin
and FGF-1 in the ternary complex (Figure 2d), where the
positively charged surfaces of FGF-1 and FGFR — rich
in lysine and arginine sidechains — are brought into close
proximity (Figures 2 and 3b). In FGF-1, this surface is
known to form the high-affinity binding site for heparin
and, as a result of the superposition relative to the inter-
leukin-1 receptor complex, the negatively charged
heparin is positioned between the positively charged sur-
faces of FGF-1 and FGFR4. The heparin-binding sur-
faces in the FGFR4–FGF-1 complex partly replace the
close interactions of IL-1β with the Ig1 domain and the
cleft between Ig1 and Ig2 of IL1R. Indeed, the loops
from FGF-1 in this region are shorter than those found in
IL-1β. Thus, the superposition of the FGFR4 model and
FGF-1–heparin crystal structure on the IL1R–IL-1β
complex provides compelling evidence that the general
mode of binding of FGFs to their high-affinity receptors
is similar to that seen for IL-1β binding to IL1R. In addi-
tion, given that heparin is sandwiched between FGF-1
and FGFR4, it is unlikely that the trans orientation of the
FGF-1–heparin–FGF-1 dimer found in the crystal struc-
ture [10] is relevant to receptor–FGF-1 dimer formation
(see Figure 3h of [10]): FGFR4 would bind in place of the
second FGF-1 instead. To support these assertions, the
model of the FGFR4–heparin–FGF-1 complex is in
agreement with many of the published mutagenesis
results on FGFR–heparin–FGF interactions (Table 1).
Experimental evidence supporting the model for the
ternary complex
Two receptor-binding sites have been identified on the
surface of FGF-1 and FGF-2: a primary, high-affinity site
and a secondary, low-affinity site [18–20]. The high-affin-
ity site consists mostly of hydrophobic amino acid
residues, which contribute approximately 75% of the
binding energy of the FGF-2 high-affinity site for the
receptor [19]. These residues are well conserved between
FGF-1 (residues Tyr15, Tyr94, Leu133, Leu135) and
FGF-2 (residues Tyr24, Tyr103, Leu140, Met142). The
high-affinity site hydrophobic contact is partly conserved
in the IL1R–IL-1RA complex crystal structure [9], where
two residues in IL-1RA, Trp16 and Tyr147, correspond to
Tyr15 and Leu133 in FGF-1, and form hydrophobic con-
tacts with Leu112, Pro113 and Leu198 in domain Ig2 of
IL1R. In our model of the FGFR4–heparin–FGF-1
complex, the high-affinity site of FGF-1 packs against
Ala161, Val162, Pro163 and Leu242 in the Ig2 domain of
FGFR4 (residues conserved in FGFR1–3). Val162, Pro163
and Leu242 in FGFR4 are structurally equivalent to the
three residues forming the hydrophobic ligand-binding
surface in IL1R (Leu112, Pro113 and Leu198; Figure 1).
Part of the FGF-binding hydrophobic patch in the
FGFR4 model (Ala161–Val162–Pro163, above) lies in the
middle of an 18-residue-long sequence ‘K18K’ on the first
two β strands of Ig2, which face FGF-1 in the ternary
complex model, and have been identified through site-
directed mutagenesis and peptide mapping as necessary
for both heparin and FGF binding [1]. Residues along this
sequence, plus other positively charged residues from
FGFR4, totalling around 13 lysine and arginine sidechains
(among other sidechains capable of forming hydrogen
bonds with heparin), form a heparin-binding channel —
the contribution of FGFR to the electrostatic sandwich
(Figures 1 and 2d). Mutation of lysine residues of the
K18K sequence in FGFR1 (160-KMEKKLHAVPAAK-
TVKFK-176 corresponding to 155-RMEKKLHAVPAG-
NTVKFR-171 in FGFR4; sequence in single-letter amino
acid code) either abrogated or significantly reduced both
heparin and FGF binding to the receptor [1]. The model
structure in Figure 2c rationalizes these observations: the
basic residues Arg155, Lys158, Lys159, Lys169 and
Arg171 of FGFR4 are in close proximity to the FGF-1
heparin-binding site and can form electrostatic interac-
tions with the sulphate groups of heparin located in
between the receptor and FGF.
A secondary low-affinity receptor-binding site found on
the surface of FGF-2, the 110-KYTSW-114 loop, was origi-
nally identified by screening a library of phage-displayed
FGF-2 epitopes with anti-FGF-2 antibodies [18]. Syn-
thetic peptides corresponding to this epitope block
binding of FGF-2 to FGFR1 [18]. Mutagenesis indicated
that the site is required for mitogenic activity, but not for
receptor or heparin binding [19]. In FGF-1, the loop is two
amino acids longer (101-KHAEKNW-107) and is the only
region in the backbone of the two crystal structures [10,17]
where the conformation differs. Replacing the loop in
FGF-2 with that from FGF-1 led to FGF-1-like binding to
keratinocyte growth factor receptor (KGFR, a splice
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variant of FGFR2 [20]), strongly suggesting that the loop
is involved in receptor selectivity. In the ternary complex
structure presented here, the low-affinity site is solvent-
exposed but, as we shall show below, the low-affinity site
can come into contact with a second receptor molecule in
only one of the proposed dimer models (Figure 4a). This
agrees with the observation that the low-affinity site is
necessary for signal transduction through receptor dimer-
ization but not for binding of FGF to the receptor [19].
Replacing one residue, Glu96 in FGF-2, identified as essen-
tial for receptor binding through site-directed mutagenesis,
with alanine reduced the affinity of FGF-2 for FGFR1
1000-fold compared with the wild-type factor [21]. In FGF-
1, the equivalent Glu87 is solvent-exposed in an earlier
model [22] of the FGF–FGFR–heparin ternary complex
and does not contact the receptor. Instead, molecular
dynamics simulations and deletion mutagenesis on FGF-1
led the authors [22] to propose that Glu87 is essential for the
Research Article  A model for the FGFR–heparin–FGF complex Huhtala, Pentikäinen and Johnson    703
Figure 3
The model of the ternary complex formed by
FGFR1, FGF and heparin. (a) Stereoview Cα
atom trace of the FGFR4–FGF-1 complex
model. For clarity, heparin is not shown in this
view. (b) Stereoview of the electrostatic
surface of the FGFR4–FGF-1 complex with
bound dodecasaccharide fragments of
heparin shown in a ball-and-stick
representation. This model of the complex is
based on the relative orientation of IL-1β
bound to IL1R; it can be seen that the inner
surface of Ig3 of FGFR4 matches the surface
contours of FGF-1. The figure was prepared
using MOLSCRIPT [35], GRASP [37], and
the RASTER3D package [36].
structural integrity of FGF-1, forming a surface intramolecu-
lar salt bridge with Lys12 (Lys21 in FGF-2); but a salt
bridge is not seen in any of the crystal structures. In con-
trast, our model positions both Glu87 and Lys12 in contact
with domain Ig3 of FGFR4, as one might expect for a con-
served critical residue in which mutagenesis severely affects
receptor binding.
In the ternary model of the complex, and in the vicinity
of Glu87 in FGF-1, the sequence 273-VYSDAQPHI-281
is located in the N-terminal half of the Ig3 domain. This
sequence was mutated to ASQKKSIQF [2], the corre-
sponding sequence in the first Ig domain of human CD4.
The mutant receptor lost its ability to bind FGF
although heparin binding was not only unaffected but
actually served to activate the mutant receptor [2]. The
current ternary model accommodates these results well:
residues 273–281 of FGFR4 face FGF-1 but are far
removed from the heparin-binding surfaces formed by
domains Ig2 and Ig1.
Stoichiometry of the dimeric receptor complex
Key to the modelling of the ‘active’ receptor complex is
the stoichiometry of FGFR to FGF. A 2:1 FGFR:FGF
stoichiometry was proposed on the basis of isothermal
titration calorimetry [19,23]. In this model [23], a single
FGF is docked outside of the two Ig2–Ig3 ‘elbows’ of
their dimer, on the opposite face of the receptor compared
with the X-ray structure of the IL1R–IL-1β complex (e.g.,
FGF positioned at the arrow in Figure 4d). An analogous
arrangement was observed in the X-ray structure of the
complex of human growth hormone (HGH) with a dimer
of the extracellular domains of its receptor (HGHR) [24].
Although HGHR is composed of Ig-like domains, as are
IL1R and FGFR, HGH is an α-helical structure and
shares no structural similarity with FGF and IL-1β. 
Considerable evidence also supports the formation of a 2:2
FGFR–FGF complex [3,25–27] and the formation of FGF-
free FGFR4 receptor dimers in the presence of longer
heparin molecules [2]. Most evidence supports strong
heparin–FGF, FGFR–heparin, and FGF–FGFR binding
interactions, but much less strong interactions between
FGF molecules. This is certainly reflected in the crystal
structures of heparin–FGF complexes and FGF crystals
without heparin: the main binding mode is to heparin and
not between FGF molecules. FGFs have been observed to
self-associate on short heparin-like saccharides in the trans
[10] orientation (from the opposite sides of the heparin
fragment). In contrast, the cis orientation places two FGFs
head-to-tail in an asymmetric dimer on the same side of a
larger heparin fragment (based on non-dimeric crystal con-
tacts of FGF-2 [25]), a mechanism thought to lead to
dimerization of FGFRs [3,25,26]. Consistent with this
assertion, short synthetic heparin analogues inhibit recep-
tor dimerization [3], but this is in agreement with many
other models too. Evidence for the cis head-to-tail FGF
dimer orientation is extremely weak, however, and homo-
dimeric FGF structures have not been observed.
Structural models for the dimeric receptor complex
In Figure 4, we show the different dimeric models that
can be made given the ternary model of the monomer con-
structed on the basis of the IL1R–IL-1β complex struc-
ture and the assumption that the 2:2 complex is indeed
formed. Each dimer model is constructed on the basis of
our tertiary complex model in which the electrostatic
sandwich and complementarity between the major FGFR
and FGF binding sites are key features. Dimeric models
in Figure 4c–e are based on predictions made by others.
The head-to-head model version 1 (Figure 4a) was our
first attempt to form a symmetric dimer based on the
model of the ternary complex. Note the location of the
N termini on the dimer in this model relative to the
other models and to the monomer in Figure 2c. In
Figure 4a, there is a continuous heparin channel through
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Table 1
The main experimental features supported by the ternary
complex and dimeric models.
Model
a b c d e
Ternary complex
Heparin sandwiched between + + + + +
positive charges
High-affinity site contact + + + + +
Glu87, Lys12 in FGF-1 at + + + + +
FGFR4 interface
K18K heparin-binding motif + + + + +
FGFR4 residues 273–281 + + + + +
Dimer complexes
FGF low-affinity site contact + – 1/2 – –
to FGFR
FGFR4 Ser338, Leu341 + – – – –
contacts low-affinity site
Heparin channel-spanning + + + – +
complex
Transmembrane helices + + + + –
in proximity
Compatibility with five putative 5/5 4/5 5/5 4/5 5/5
glycosylation sites
Homeo-interaction sequences – – – + –
in contact
Spanning heparin units 
Units bound to FGF-1 at 5 (2 ×) 5 (2 ×) 5 (2 ×) 5 (2 ×) 5 (1 ×)
primary site
Additional units bound to 7 (2 ×) 7 (2 ×) 7 (2 ×) 7 (2 ×) 7 (2 ×)
FGF-1–FGFR4
Channel sequence of 7557 5775 7575 75 (2 ×) 757
bound units
Total saccharide units in 24 24 24 24 19
dimer model
The main features of the ternary complex models shown in Figure 4
(panels a–e).
the dimer (24 bound saccharide units), and the low-affin-
ity site of FGF from one ternary complex is in contact
with the receptor (Ig3) from the second ternary complex,
and vice versa.
The contact surface lies in the C-terminal half of Ig3,
which is encoded by alternative exons termed IIIb and
IIIc in the transmembrane forms of FGFRs 1 and 2 [14].
The switch from one exon to another changes the speci-
ficity of the receptor towards the various FGF ligands,
and in turn the low-affinity site on FGFs is known to
affect the specificity of receptor binding [20,28]. Thus, it
is an attractive idea that the alternative C-terminal
sequences in Ig3 of FGFR and the low-affinity loop on
FGF should be brought into intimate contact and thereby
determine the specificity of the receptor for its ligand. A
double mutant of KGFR (IIIb variant of FGFR2),
Tyr345→Ser; Gln348→Ile, corresponds to a switch from
the IIIb to the IIIc sequence. This mutant has been
shown to have significant affinity for FGF-2, as is the case
for FGFR2 containing the IIIc sequence, but unlike
native KGFR [24]. These residues have been predicted,
independent of the mutagenesis experiments and on the
basis of sequence conservation in each of the IIIb and IIIc
sets of splice variants, to participate in ligand binding [14].
The corresponding two residues in the invariant FGFR4
sequence, Ser338 and Leu341 (Figure 1), are positioned
directly in contact with the FGF-1 low-affinity site in the
dimer in Figure 4a, supporting the notion that this region
participates in interactions that determine specificity in
the dimeric receptor complex.
The FGFR4 ectodomain has five signal sequences for N-
linked glycosylation that are exposed on the surface of the
ternary complex model, but the identity of those sites that
are indeed glycosylated in the native protein is not known
at this time. All five sites are accessible to solvent on the
surface of both the ternary complex and the dimer shown
in Figure 4a and are potentially available for glycosylation.
The head-to-head model version 2 (Figure 4b) is related
to version 1 (Figure 4a) by a 180° rotation of both
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Figure 4
Possible dimeric receptor models of the FGFR4–heparin–FGF-1
dimer constructed on the basis of the model of the ternary complex
shown in Figure 2c. (a) The dimeric arrangement of the receptor
most consistent with published experimental data. (b) As in (a) but
rotated by 180°. (c–e) Dimeric models based on previously
published predictions (see text). Side views of the dimers with Ig3
positioned at the bottom of each figure are shown in the upper row.
The view from the top of each receptor dimer model is shown in the
lower row. The N terminus of FGFR4 is indicated. The figure was
prepared using MOLSCRIPT [35].
monomers along the long axis of the modelled receptor.
This model also has a good dimer interface between
domains Ig2 and Ig3 and a continuous heparin channel (24
bound saccharide units), but the FGF low-affinity sites are
exposed to solvent and do not form dimeric contacts.
Moreover, one of the potential glycosylation sites in
FGFR4, Asn112 in Ig1 (Figure 1), is buried in the receptor
dimer interface.
The head-to-tail dimer model (Figure 4c) was constructed
around one protein–protein interface found in the crystal
contacts of FGF-2 crystals. FGF-2 has crystallized only as
a monomer in the asymmetric unit, and two interfaces
conserved in five triclinic crystal forms of human and
bovine FGF-2 correspond to translations of one unit cell
along the 33 Å and 31 Å long unit cell axes [25]. FGF-2
dimers constructed with either interface have the high-
affinity heparin-binding sites aligned such that the dimer
can bind cis to a decasaccharide heparin fragment [25].
A dimer formed from the ternary complex cannot be con-
structed with the 33 Å interface, which would place one of
the receptor molecules in the space occupied by the FGF
of the other monomer. The model in Figure 4c in based
on the interface along the 31 Å axis. The dimer model is
formed in a head-to-tail manner with respect to the
ternary complex monomers, which leaves one of the two
dimer interfaces completely exposed to solvent. This
model would predict the formation of higher order
oligomers, not just dimers. Residues forming FGF-2
crystal contacts are not well conserved in FGF-1, and
none of the known FGF-1 crystal structures either has tri-
clinic space groups or shows conservation of the 31 Å
interface, all contrary to what would be expected if this
was the general mode for FGF dimerization.
Mutagenesis experiments have implicated the interdomain
region between Ig2 and Ig3 and the first β strand of Ig3 as
a ‘homeo-interaction sequence’ for FGFR dimerization
[29]. The sequence 249-ERSPHRPILQAGLPANK-265
in FGFR1 (residues 243–259 in FGFR4, completely con-
served except for the Lys265→Thr259 substitution) was
shown to be required for receptor–receptor interaction by
deletion experiments. This observation was confirmed by
randomizing the sequence in two parts and examining
ligand binding, receptor–receptor interaction and mito-
genic activity of the mutant receptors [29].
An earlier model of the FGF–FGFR–heparin ternary
complex has been constructed to juxtapose the heparin-
binding sites of FGF and FGFR [22,30] and a dimer was
built using the homeo-interaction sequences as the dimer
interface, which places the two receptors in a ‘back-to-
back’ orientation. In such a dimer, a continuous heparin-
binding channel is formed that extends through the two
receptors [30]. The orientation of FGF in the Ig2–Ig3
‘elbow’ of their ternary complex, however, is entirely dif-
ferent from our current model based on the IL1R–IL-1β
complex structure.
The back-to-back model (Figure 4d) is based on the pro-
posal that dimeric interactions take place between the
homeo-interaction sequence of the receptor of each
ternary complex monomer [30]. Coincidentally, this orien-
tation resembles the HGHR complex [24], except that two
FGF-1 molecules would bind to the ‘sides’ of the receptor
dimer instead of the one FGF-1 at the ‘top’ of the
complex (arrow in Figure 4d). Although derived from our
ternary complex model, back-to-back dimerization is not
compatible with much of the experimental evidence: the
two heparin-binding sites forming the electrostatic sand-
wich in the dimer monomer are placed far apart in the
dimer and no heparin-binding channel is formed. This
model would not account for heparin-induced dimeriza-
tion and the blockage of dimer formation by short heparin
fragments. Furthermore, this dimer model leaves the FGF
low-affinity sites solvent-exposed and offers no explana-
tion for their observed effects on receptor binding. The
homeo-interaction sequence also contains one of the
potential N-linked glycosylation sites (Asn258; Figure 1),
which is positioned at the dimer interface in Figure 4d.
None of the other dimer models studied here
(Figures 2a,b,c,e) has the homeo-interaction sequences
positioned at the receptor dimer interface. But the muta-
genesis results on the homeo-interaction sequence can be
partly explained in terms of our current model of the
monomeric ternary complex. Scrambling of the first half of
the homeo-interaction sequence (ERSPHRPI) prevented
FGF binding [29], as would be expected given that this
sequence is facing the growth factor at the Ig2–Ig3 inter-
domain linker. Ligand binding was not affected by muta-
tion of the second half (LQAGLPAN) to a foreign
sequence [29] and, in our ternary complex model, this
sequence is positioned on the opposite face of Ig3 with
respect to FGF.
The mode of dimerization shown in Figure 4e is based on
the crystal structure of human FGF-1 [10], where FGF-1
crystallized as a dimer linked through a short heparin frag-
ment. In this crystal structure, there is no FGF–FGF
protein–protein interface and the high-affinity heparin-
binding sites from the two FGF-1 molecules are facing the
same heparin fragment but from opposite sides. The
authors propose trans binding of FGF about heparin as the
mechanism for FGF-mediated FGFR dimerization, but
this seems unlikely. In their model [10], no direct interac-
tions between FGFR and heparin need take place, and
this does not agree with the experimental evidence
[1,2,23]. It is sterically impossible to build a dimer of our
ternary complex in the proposed orientation, because
domains Ig1 and Ig2 of one FGFR in one monomer would
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occupy the same space as FGF-1 in the other monomer,
and vice versa. Furthermore, the C-terminal attachment
points for the transmembrane helices of the two receptor
molecules would point in nearly opposite directions (model
not shown). If both FGFs are rotated towards each other,
however, such that heparin occupies a crevice formed by
the two heparin-binding sites, then a dimer can be con-
structed using our ternary complex model (Figure 4e).
Although there is a continuous heparin channel formed (19
saccharide units, five shared by the two FGF-1 molecules),
there are few contacts made between the two FGFR4 mol-
ecules, the low-affinity sites are exposed to solvent, and
the C termini are far from each other.
In Table 1, we have summarized the main experimental
features that the ternary complex and a dimeric model
should account for and how well each of the models fulfils
these requirements. The ternary FGFR4–heparin–FGF-1
complex, based on the X-ray structure of the homologous
interleukin receptor–ligand complex, used to build each of
the five dimer models, accommodates all of the main
experimental features. Models a–c and e can explain not
only the 2:2 complex, but also the variable stoichiometry
that has been observed: FGF-free dimerization via the
long heparin channel (2:0 stoichiometry), and 2:1 
stoichiometry, a precedent in the heterodimeric
IL1R–IL1RAcP case. In terms of the dimers, our present
‘best bet’ is the symmetric dimer illustrated in Figure 4a.
This model accommodates a long single heparin channel
that extends from one edge of the receptor to the other
and is the only model that places the low-affinity site of
FGF-1 from one ternary complex in contact with the
receptor of the second complex. Given the evidence pre-
sented here (Table 1), both the head-to-tail cis and the
trans FGF–heparin orientations [31] are unlikely to occur
in FGFR–FGF complexes. The first is based on very
weak data on crystal contacts and the trans orientation
might simply be misleading, the result of crystallization
with a simple multivalent ligand, and not relevant in its
entirety to the biological case.
Here, we have attempted to rationalize much of the
experimental data within a reasonable ternary complex
model, based on a homologous complex, which leads to
the formation of a positively charged channel with
heparin bound within. Five alternative dimer complexes
can be built using the ternary complex, and one of these
clearly agrees best with the experimental data — the
model shown in Figure 4a. The FGFR–heparin–FGF
story is clearly a complicated one, that is often muddied
by conflicting evidence. In the absence of a crystal
structure of the complex, however, each of the five
models predicts specific interactions and behaviour that
can be tested experimentally, and the models help to
clarify the mode of receptor activation in the fibroblastic
receptor family.
Biological implications
Fibroblast growth factor (FGF) signalling normally
functions in a number of key biological responses includ-
ing cell growth and differentiation, angiogenesis, the sur-
vival of neurons and wound repair, whereas abnormal
expression of FGFs leads to pathological conditions
including heart disease, cancer and disease of the retina.
The receptors for FGFs, FGFRs, are located within the
cell membrane and transduce the external signal pro-
vided by growth-factor binding into autophosphorylation
of the intracellular tyrosine kinase domains. FGF recep-
tor activation is dependent on heparan sulphate chains of
cell-surface proteoglycans or similar molecules such as
heparin. The activation of the tyrosine kinases initiates a
host of cellular responses to the original signal.
To date, no structure for the FGFR–heparin–FGF
ternary complex or a higher order complex yet exist.
Nonetheless, various models have been proposed. Here,
we propose a model for the ternary complex based on the
homologous relationships between the growth factors
FGF and interleukin-1β (IL-1β), their receptors FGFR
and IL1R, and the crystal structure of the IL-1β–IL1R
binary complex. The relationship between the inter-
leukin receptor and FGFR is undisputed, as is the rela-
tionship between the FGF family and IL-1β. When a
model constructed for FGFR and the crystal structure of
FGF-1 with bound heparin are superposed onto IL-1β
and IL1R in the complex, the negatively charged heparin
fits into a channel between FGF-1 and FGFR that is
very rich in positively charged residues, half contributed
by the receptor and half by the growth factor. Further-
more, experimental results reported by others are in
agreement with this model complex.
Most experimental evidence is consistent with a dimer
involving two FGFR monomers, but data suggest that
one, two, or no FGF monomers can be present; heparin
can be present alone or in combination with FGF. A rea-
sonable dimer model constructed on the basis of two
FGFR–heparin–FGF ternary complex ‘monomers’
can be assembled in five different ways. Only one of these
complexes is consistent with the majority of the experi-
mental results. In that complex, FGF makes tight interac-
tions with both heparin and FGFR, but interactions
between FGF monomers are not so important, consistent
with the lack of true dimeric interactions in any of the
FGF crystal structures reported to date. The dimer model
can also accommodate heterodimers of the FGFR iso-
types, which have been observed in some experiments
and are analogous to the IL1R–IL1RAcP heterodimer,
in which only one cytokine molecule is bound. This pro-
posed structure for an FGFR–heparin–FGF complex is
based on interactions observed in the homologous inter-
leukin–cytokine complex defined by crystallography.
These results lead to a rational interpretation of seemingly
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conflicting experimental data, which will be useful in
understanding the role and mechanism of action of these
receptors in the cell.
Materials and methods
The homology model for FGFR4 was based on the crystal structure of
the type-I interleukin-1 receptor–interleukin-1β complex [8] (PDB entry
code 1ITB). The structure of telokin [15] (PDB entry code 1TLK) was
used to help assign the positions of key residues and help parse the
gaps and loop regions in the sequence alignment. Sequences of
FGFR4, IL1R and telokin were aligned with the program MALIGN
[32,33] and manually revised to correspond to a structural superposi-
tion of the telokin crystal structure, which consists of one I-set Ig-like
domain, to each of the Ig domains of IL1R. The resulting alignment of
FGFR4 with the IL1R template structure was used to carry out spatial
restraints based homology modelling with the program MODELLER
[34]. The structure of IL-1β in the IL1R–IL-1β complex was replaced
with one FGF-1 molecule from the FGF-1–heparin–FGF-1 crystal
structure [10] (PDB entry code 1AXM) by superposing FGF-1 onto
IL-1β prior to modelling FGFR4. This enabled the contacts between
FGFR4 and FGF-1 to be taken into account during the modelling cal-
culations. Energy minimization of the receptor model was carried out in
MODELLER. The 28 residues from the interdomain linker between Ig1
and Ig2 in FGFR4 were not modelled, this linker is 26 amino acid
residues longer than in IL1R, and there is no structural information
available for this region. FGFR4 from the ternary complex model super-
poses with IL1R over 283 matched Cα atom pairs with an rmsd of
0.8 Å (3.0 Å cut-off).
The dimeric FGF-1–heparin–FGF-1 crystal structure [10] complex
shows five ordered saccharide units bound between the high-affinity
heparin-binding sites of the two FGF-1 molecules in the dimer. A part
of this crystal structure, containing one FGF-1 and the heparin pen-
tasaccharide, was used to build the receptor complex and to find the
exact position of heparin. A model of a 12 saccharide unit long
heparin chain was constructed and superposed on the heparin frag-
ment present in the FGF-1 crystal structure [10] of the
FGFR4–FGF-1 complex using the program SYBYL (Tripos Assoc.,
USA). The overhanging heptasaccharide part of the heparin chain
was then manually docked into the positively charged heparin-binding
channel formed in the FGFR4 model and energy minimised locally
using the TRIPOS force field in SYBYL to remove atom clashes. The
docking required no other manipulations of the receptor model. Five
different dimeric receptor complex models were also constructed
using SYBYL. Protein–protein interfaces between the two identical
monomeric ternary complexes in each of the dimer models were not
refined further. 
Structures were superposed with the program VERTAA (JV Lehtonen
and MSJ, unpublished observations). Figures were prepared using
MOLSCRIPT [35], the RASTER3D package [36] and GRASP [37]
and the alignment was formatted with ALSCRIPT [38]. Residue num-
bering cited in the text follows from: FGFR1-4, beginning from the N-
terminal Met; FGF-1 [10]; FGF-2 [15]; IL1R and IL-1β [5]; IL1RA [6],
KGFR [24].
Accession numbers
Coordinates of the model in Figure 4a have been deposited with the
Brookhaven Protein Data Bank with accession code 1QCT.
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